JPRN-jRCT2033260314 Investigational Regimen Hemophilia B Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines JPRN-jRCT2033260314—A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why JPRN-jRCT2033260314 is a hot trial to watch

Hemophilia B is increasingly segmented by mechanism, biomarker, line of therapy, geography and endpoint architecture. JPRN-jRCT2033260314 is notable because it tests Investigational Regimen in a Phase 3 design while *Incidence of thromboembolic events [Time Frame: Day 1 to 10 years] *Incidence of factor inhibitor development [Time Frame: Day 1 to 10 years] -FIX inhibitor development was defined as an inhibitor titer >= 0.6 Bethesda units per milliliter (BU/mL). *Incidence of hepatic malignancy [Time Frame: Day 1 to 10 years] *Incidence of liver abnormalities [Time Frame: Day 1 to 10 years] *Factor activity level [Time Frame: Day 1 to 10 years] -Factor activity level will be reported. Factor levels may be measured using different assay methods including a one-stage assay or by chromogenic substrate assay and a second one-stage assay. serves as the main decision variable. The value of this program will depend on whether the protocol converts biological rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add mechanism, development-status and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. Allocation is Non-Randomized, masking is Open Label, and the intervention model is Single Group Assignment. Enrollment of 173 participants across Turkey, Australia, United States, Japan shapes statistical precision, execution risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

• Primary: *Incidence of thromboembolic events [Time Frame: Day 1 to 10 years] *Incidence of factor inhibitor development [Time Frame: Day 1 to 10 years] -FIX inhibitor development was defined as an inhibitor titer >= 0.6 Bethesda units per milliliter (BU/mL). *Incidence of hepatic malignancy [Time Frame: Day 1 to 10 years] *Incidence of liver abnormalities [Time Frame: Day 1 to 10 years] *Factor activity level [Time Frame: Day 1 to 10 years] -Factor activity level will be reported. Factor levels may be measured using different assay methods including a one-stage assay or by chromogenic substrate assay and a second one-stage assay.
• Primary: ＊血栓塞栓性事象の発現頻度［期間：第1日～10年］ ＊凝固因子インヒビターの発生頻度［期間：第1日～10年］ －FIXに対するインヒビターの発現は、インヒビターの力価が0.6ベセスダ単位/mL（BU/mL）以上と定義 ＊肝悪性腫瘍の発現頻度［期間：第1日～10年］ ＊肝異常の発現頻度［期間：第1日～10年］ ＊凝固因子活性レベル［期間：第1日～10年］ －凝固因子活性レベルを報告する。因子活性レベルは、凝固一段法、合成基質法又は別条件の凝固一段法など、異なる測定法を用いて測定される場合がある。
• Secondary: ＊すべての出血（治療を要した出血及び治療を要しない出血）の年間出血率（ABR）［期間：第1日～10年］ －ABR:1年あたりの出血エピソード数。治療を要した出血及び治療を要しない出血の両方を含む。 　ABR（1年あたりの出血エピソード数）は、各治験参加者について、各観察期間ごとに以下の式を用いて算出する。 　ABR = (出血回数 / 観察期間の日数) x 365.25 （日/年） ＊ベクター投与を受けてから定期補充療法再開までの期間及びその頻度［期間：第1日～10年］ －ベクター投与を受けてから定期補充療法を再開するまでの時間（日数）及びその頻度を記述する。 ＊外因性凝固因子の年間投与率（AIR）［期間：第1日～10年］ －AIR（1年あたりのFIX投与回数）は、各治験参加者について、各観察期間ごとに以下の式を用いて算出する。 　AIR = (FIX投与回数 / 観察期間の日数) x 365.25（日/年） ＊外因性凝固因子の使用量［期間：第1日～10年］ －年間総凝固因子使用量（国際単位IU）は、各治験参加者について、各観察期間ごとに以下の式を用いて算出する。 年間総凝固因子使用量 = (投与されたFIXの総量(IU) / 観察期間の日数) x 365.25（日/年） ＊肝臓以外の悪性腫瘍の発現頻度［期間：第1日～10年］ ＊自己免疫疾患の発現頻度［期間：第1日～10年］ ＊重篤な有害事象の発現頻度［期間：第1日～10年］ －重篤な有害事象とは以下のいずれかの転帰を伴う有害事象、又は、そのほかの理由により重要と判断された有害事象である：死に至るもの、入院又は入院期間の延長が必要となるもの、生命を脅かすもの（死亡に直結する危険性があるもの）、永続的又は重大な障害・機能不全に陥るもの、先天異常を来すもの、血栓性事象の発現、凝固因子インヒビターの発現、肝悪性腫瘍の発現、免疫抑制療法によっても改善しない治験薬に関連する肝トランスアミナーゼ上昇 、 治験薬との因果関係に合理的な可能性があると判断された悪性腫瘍の発現 ＊原因を問わない死亡［期間：第1日～10年］ －原因を問わない死亡とは、治験期間中に発生したあらゆる原因による死亡である。発現率は、評価可能な事象が認められた治験参加者の総数を、対象となるコホート又は治療群における全治験参加者のリスク曝露時間の合計で除した値として定義する。 ＊EQ-5D-5Lの項目及びVASスコア［期間：第1日～10年］ －EQ-5D-5Lは5つの項目からなる健康状態評価尺度及び視覚的評価スケール（感情温度計）で構成される。5項目の健康状態分類を用いて、治験参加者は自身の健康状態のさまざまな側面に関する5つの設問に回答し、以下の事項を評価する。 　1. 移動の程度 　2. 身の回りの管理 　3. ふだんの活動 　4. 痛み／不快感 　5. 不安／ふさぎ込み
• Secondary: *Total ABR (treated or untreated) [Time Frame: Day 1 to 10 years] -ABR (Annual Bleed Rate): number of bleeding episodes per year. This includes treated and untreated bleeds. The ABR or the annualized number of bleeding episodes per year, will be derived for each participant for each observation period by using the following formula: ABR = (Number of bleeds / Days in observation period) x 365.25 days/year. *Incidence of and time from vector infusion to resumption of prophylaxis [Time Frame: Day 1 to 10 years] -Describe incidence of resumption of prophylaxis resumption and the time (in days) to resumption of prophylaxis after receiving vector infusion. *AIR of exogenous factor [Time Frame: Day 1 to 10 years] -The AIR or the annualized number of FIX infusions per year, will be derived for each participant for each observation period by using the following formula: AIR = (Number of FIX infusions / Days in observation period) x 365.25 days/year. *Consumption of exogenous factor [Time Frame: Day 1 to 10 years] -The annualized TFC in international units (IU) will be derived for each participant for each observation period using the following formula: Annualized TFC = (Total units of FIX infused (IU)/ Days in observation period) x 365.25 days/year *Incidence of Non-hepatic malignancy [Time Frame: Day 1 to 10 years] *Incidence of Auto-immune disorders [Time Frame: Day 1 to 10 years] *Incidence of SAEs [Time Frame: Day 1 to 10 years] -An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; development of a clinical thrombotic event; development of factor inhibitor; development of a hepatic malignancy; development of drug-related elevated hepatic transaminases that fail to improve with immunosuppressive regimens; occurrence of a malignancy with reasonable possibility of being related to study drug. *All cause mortality [Time Frame: Day 1 to 10 years] -All-cause mortality was defined as the death due to any cause during the course of study. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Incidence rate of all-cause deaths was reported in this outcome measure. *EQ-5D-5L dimension and VAS scores [Time Frame: Day 1 to 10 years] -The EQ-5D-5L comprises a 5-item health status measure and a visual analog rating scale/feeling thermometer. Using the 5-dimensional Health State Classification, participants are asked to respond to five questions on different aspects of their health status that assess the following: 1.Mobility 2.Self-care 3.Usual activities 4.Pain/Discomfort 5.Anxiety/Depression

Benchmark readouts in the surrounding field

• Vamorolone for Duchenne Muscular Dystrophy (Phase 2): TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028); TTSTAND velocity(12-month): Difference (LS Mean) = 0.004(95.0% CI, -0.025 to 0.032); Difference (LS Mean) = 0.001(95.0% CI, -0.027 to 0.028)
• Safety and Efficacy of Tamoxifen in Patients with Duchenne muscular dystrophy: open Label Extension of TAMDMD Trial (Phase 3): SAE = 9.0 %
• Impact and Interplay of Corticosteroid Regimen and Exercise Training on DMD Muscle Function (Phase 2): Change in BMI(Mean) = 1.8 kg/m^2 (Standard Deviation, 1.9); Change in BMI(Mean) = 0.67 kg/m^2 (Standard Deviation, 1.4)

These indexed results are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, treatment line, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Investigational Regimen — structured asset context should be refreshed as the program evolves.

Company & Deal Intelligence context: Pfizer Japan, Inc. — http://www.pfizer.co.jp

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes that connect activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

JPRN-jRCT2033260314 is a focused lens on Hemophilia B development. Its value will be determined by whether Investigational Regimen can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from existing benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.